{"hands_on_practices": [{"introduction": "The diagnosis of cutaneous lupus erythematosus often requires careful consideration of overlapping syndromes and mimics. This first exercise focuses on a key differential diagnosis, urticarial vasculitis, a condition that can be a presenting sign of SLE. By analyzing a clinical vignette with specific lesion characteristics and critical laboratory data like complement levels, you will practice linking clinical observations to underlying pathophysiological mechanisms, such as immune complex deposition and complement pathway activation. [@problem_id:4429880]", "problem": "A 34-year-old woman presents with a $3$-month history of recurrent wheals that are painful or burning, each individual lesion persisting for $>24$ hours and resolving with residual purpura and hyperpigmentation. She reports morning arthralgias and low-grade fevers. Examination finds non-blanching urticarial plaques on the trunk and proximal extremities, with scattered petechiae and post-inflammatory hyperpigmentation. Laboratory results show reduced complement levels: $C_3 = 55$ mg/dL (reference $90$–$180$ mg/dL) and $C_4 = 6$ mg/dL (reference $10$–$40$ mg/dL). No medications were started before symptom onset.\n\nUse the following foundational facts as your starting point: (i) in immune complex small-vessel vasculitis, activation of the classical complement pathway consumes complement components, lowering serum $C_3$, $C_4$, and total hemolytic complement ($CH_{50}$); (ii) urticarial vasculitis is characterized by urticarial-appearing lesions that persist for $>24$ hours, are often painful or burning, and resolve with purpura; (iii) hypocomplementemia in urticarial vasculitis is associated with systemic involvement and anti-C1q antibodies and may overlap with Systemic Lupus Erythematosus (SLE).\n\nWhich option best justifies the working diagnosis on pathophysiological grounds and proposes the most appropriate initial investigations to confirm the cutaneous vasculitis and assess for lupus-associated systemic involvement?\n\nA. The prolonged, painful wheals with purpura and low $C_3/C_4$ indicate immune complex-mediated urticarial vasculitis with classical pathway consumption, favoring the hypocomplementemic variant. Obtain a lesional skin biopsy for Hematoxylin and Eosin (H&E) histopathology and Direct Immunofluorescence (DIF), a complement panel including $CH_{50}$, serum anti-C1q antibodies, Antinuclear Antibodies (ANA) with reflex anti–double-stranded deoxyribonucleic acid (anti-dsDNA), urinalysis with urine protein-to-creatinine ratio, and serum creatinine; add Erythrocyte Sedimentation Rate (ESR)/C-Reactive Protein (CRP) to assess inflammation.\n\nB. The lesions represent chronic spontaneous urticaria with secondary bruising; low complement is incidental. Defer biopsy; order total immunoglobulin E (IgE), thyroid peroxidase antibodies, and an autologous serum skin test; initiate antihistamines and avoid further systemic evaluation initially.\n\nC. This is adult Immunoglobulin A vasculitis; urticarial lesions with purpura reflect Immunoglobulin A deposition. Prioritize serum Immunoglobulin A level and small-bowel biopsy to document mucosal Immunoglobulin A deposition; defer skin biopsy and lupus serology until later.\n\nD. Low complement suggests cryoglobulinemic vasculitis; initially order mixed cryoglobulins with cryocrit, rheumatoid factor, and Hepatitis C virus serology; if positive, no further lupus evaluation is needed unless proteinuria develops.\n\nE. The differential is dominated by Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis; order proteinase-$3$ ANCA and myeloperoxidase ANCA, chest radiography, and bronchoscopy to evaluate for pulmonary capillaritis; skin biopsy can be deferred if serology is positive.", "solution": "The clinical reasoning should begin from core definitions and well-tested facts regarding small-vessel vasculitis and complement biology. Immune complex small-vessel vasculitis (a form of leukocytoclastic vasculitis) results from deposition of antigen–antibody complexes in postcapillary venules. These immune complexes activate the classical complement pathway, consuming complement proteins, which lowers serum $C_3$, $C_4$, and total hemolytic complement ($CH_{50}$). Clinically, urticarial vasculitis is distinguished from chronic spontaneous urticaria by lesions that persist for $>24$ hours, often burn or are painful rather than purely pruritic, and resolve with purpura or hyperpigmentation due to erythrocyte extravasation and vessel wall damage. When hypocomplementemia is present (low $C_3$ and $C_4$), the entity is termed hypocomplementemic urticarial vasculitis; this phenotype is more likely to have systemic involvement and is associated with anti-C1q antibodies. Systemic Lupus Erythematosus (SLE) is a prototypic immune complex disease with classical complement consumption and can overlap with hypocomplementemic urticarial vasculitis, making lupus-directed evaluation appropriate. \n\nGiven the patient’s lesions persisting $>24$ hours, pain/burning, residual purpura, and documented low $C_3 = 55$ mg/dL and $C_4 = 6$ mg/dL, the pathophysiology aligns with immune complex-mediated urticarial vasculitis with classical complement consumption, favoring a hypocomplementemic phenotype. The initial evaluation should both confirm the cutaneous vasculitis and screen for systemic involvement including lupus nephritis, guided by first principles:\n\n1. Confirm vasculitis in the skin: Lesional skin biopsy for Hematoxylin and Eosin (H&E) to identify leukocytoclastic vasculitis with neutrophils, nuclear dust (leukocytoclasia), fibrinoid necrosis of vessel walls, and erythrocyte extravasation; and Direct Immunofluorescence (DIF) to detect immunoglobulin (often Immunoglobulin G and/or Immunoglobulin M) and complement ($C_3$) deposition around vessels, supporting immune complex vasculitis.\n\n2. Document complement pathway activation: A complement panel including total hemolytic complement ($CH_{50}$) to quantify classical pathway functional activity.\n\n3. Identify hypocomplementemic urticarial vasculitis association: Anti-C1q antibodies, which are characteristic of the hypocomplementemic urticarial vasculitis phenotype and also occur in SLE with hypocomplementemia.\n\n4. Screen for SLE overlap and renal involvement: Antinuclear Antibodies (ANA) with reflex anti–double-stranded deoxyribonucleic acid (anti-dsDNA) given the link to immune complex disease and hypocomplementemia; urinalysis with protein quantification (e.g., urine protein-to-creatinine ratio) and serum creatinine to evaluate for lupus nephritis or vasculitic kidney involvement.\n\n5. Assess inflammatory activity: Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP), recognizing ESR often rises in SLE and immune complex vasculitis.\n\nOption-by-option analysis:\n\nA. This option explicitly ties the clinical phenotype (urticarial plaques lasting $>24$ hours, pain, purpura) to immune complex vasculitis with classical pathway consumption, rationalizing the hypocomplementemic subtype. It proposes a comprehensive, appropriate initial workup: H&E and DIF skin biopsy to confirm leukocytoclastic vasculitis with immune complex deposition; complement functional assessment ($CH_{50}$); anti-C1q to support hypocomplementemic urticarial vasculitis; lupus-directed serology (ANA with reflex anti-dsDNA); and renal screening (urinalysis with protein quantification and serum creatinine), plus ESR/CRP. This aligns with foundational immunology and the clinical scenario. Correct.\n\nB. This treats the presentation as chronic spontaneous urticaria, but key distinguishing features contradict that diagnosis: lesion duration $>24$ hours, pain/burning, and purpura indicate vascular injury rather than simple wheal-and-flare mast cell disease; moreover, hypocomplementemia is not incidental in this context. Deferring biopsy and omitting vasculitis and lupus evaluation fails to follow from the fundamental pathophysiology. Incorrect.\n\nC. Immunoglobulin A vasculitis can cause palpable purpura and sometimes urticarial lesions, but the dominant adult presentation of painful wheals persisting $>24$ hours with prominent hypocomplementemia points toward urticarial vasculitis. Prioritizing serum Immunoglobulin A and small-bowel biopsy (for mucosal Immunoglobulin A deposition) is not the appropriate initial approach; cutaneous biopsy and complement/lupus evaluation should precede or supersede gastrointestinal biopsy in this context. Incorrect.\n\nD. Mixed cryoglobulinemic vasculitis can feature low complement (often low $C_4$) and purpura and is associated with Hepatitis C virus; ordering cryoglobulins and viral serology is reasonable in a differential workup. However, presented as a stand-alone initial plan that displaces skin biopsy, anti-C1q, ANA/anti-dsDNA, and renal assessment, it is incomplete and misaligned with the most likely diagnosis derived from the clinical phenotype and diffuse hypocomplementemia ($C_3$ and $C_4$ both low). Incorrect.\n\nE. Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitides typically cause palpable purpura but do not present with urticarial plaques that persist $>24$ hours with hypocomplementemia due to classical pathway consumption. Pulmonary capillaritis workup is not a first step absent relevant symptoms or signs, and deferring skin biopsy is not justified. Incorrect.\n\nTherefore, option A best captures the reasoning from foundational immunology and dermatopathology and proposes the correct, comprehensive initial investigation set for hypocomplementemic urticarial vasculitis in the context of potential Systemic Lupus Erythematosus overlap.", "answer": "$$\\boxed{A}$$", "id": "4429880"}, {"introduction": "Once a diagnosis of cutaneous lupus is made, objectively measuring its impact is crucial for guiding therapy and monitoring outcomes. This practice introduces the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the standard tool for this purpose. You will calculate a score based on the \"damage\" domain, reinforcing the critical distinction between reversible inflammation and irreversible sequelae like scarring, a concept fundamental to setting realistic treatment goals. [@problem_id:4429851]", "problem": "A patient with systemic lupus erythematosus presents with cutaneous findings consistent with discoid lupus erythematosus. The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) partitions severity into an activity component and a damage component. For the purposes of this calculation, use the following validated damage scoring rules that apply to scarring and atrophy from discoid lupus erythematosus plaques and to scarring alopecia, noting that the damage component is additive across domains:\n\n1. Scarring or atrophy attributable to discoid lupus erythematosus plaques is scored per anatomic region: assign $1$ point if there are $\\leq 4$ plaques with scarring/atrophy in that region; assign $2$ points if there are $\\geq 5$ plaques with scarring/atrophy in that region. Points are summed over involved regions. For this patient, all plaques are confined to a single anatomic region.\n2. Scarring alopecia on the scalp is scored by the longest diameter of the largest contiguous scarred alopecic area: assign $1$ point if the longest diameter is $< 10\\ \\mathrm{cm}$; assign $2$ points if the longest diameter is $\\geq 10\\ \\mathrm{cm}$.\n\nThe patient has $8$ discrete discoid plaques with central scarring localized to the cheeks (one anatomic region for scoring purposes) and a single area of scarring alopecia on the scalp measuring $5\\ \\mathrm{cm}$ in its longest diameter.\n\nStarting from the definition of the CLASI damage component as an additive index of scarring/atrophy across defined domains, derive the total CLASI damage score for this patient under the provided rules. Express the final CLASI damage score as an exact integer with no units. No rounding is required.\n\nThen, explain, using first principles of how damage differs from activity in cutaneous lupus erythematosus and how validated indices are used in clinical decision-making, how the magnitude of the damage score should guide the intensity of therapy in a scientifically justified manner without proposing a specific treatment plan.", "solution": "The problem will be validated by first extracting the given information and then assessing its scientific grounding, consistency, and completeness.\n\n### Step 1: Extract Givens\n- **Disease Context**: The patient has systemic lupus erythematosus with cutaneous findings of discoid lupus erythematosus.\n- **Scoring Index**: The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), specifically its damage component.\n- **Property of Score**: The damage component is additive across domains.\n- **Scoring Rule 1 (Discoid Plaques)**: For scarring or atrophy from discoid lupus erythematosus plaques, scored per anatomic region:\n    - Assign $1$ point if there are $\\leq 4$ plaques in a region.\n    - Assign $2$ points if there are $\\geq 5$ plaques in a region.\n- **Patient Data for Rule 1**:\n    - The patient has $8$ discrete discoid plaques with central scarring.\n    - All plaques are confined to a single anatomic region (the cheeks).\n- **Scoring Rule 2 (Scarring Alopecia)**: For scarring alopecia on the scalp, scored by the longest diameter of the largest contiguous scarred alopecic area:\n    - Assign $1$ point if the longest diameter is $< 10\\ \\mathrm{cm}$.\n    - Assign $2$ points if the longest diameter is $\\geq 10\\ \\mathrm{cm}$.\n- **Patient Data for Rule 2**:\n    - The patient has a single area of scarring alopecia on the scalp.\n    - The longest diameter of this area is $5\\ \\mathrm{cm}$.\n- **Tasks**:\n    1. Derive the total CLASI damage score for the patient.\n    2. Explain how the magnitude of the damage score guides the intensity of therapy, based on first principles of the distinction between damage and activity.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is subjected to validation against established criteria.\n\n- **Scientific Grounding**: The problem is scientifically grounded. The CLASI is a real, validated, and widely used instrument in dermatology and rheumatology for quantifying the state of cutaneous lupus erythematosus. The fundamental distinction between disease \"activity\" (reversible inflammation) and \"damage\" (irreversible tissue destruction like scarring) is a core principle in the management of chronic inflammatory diseases. The patient presentation and scoring rules, while potentially simplified from the full CLASI instrument for the purpose of the problem, are clinically plausible and internally consistent.\n- **Well-Posedness**: The problem is well-posed. It provides a clear, algorithmic set of rules and the specific data required to apply them. The calculation required is simple arithmetic, and the structure of the problem leads to a single, unique numerical answer for the score. The second part of the question asks for a conceptual explanation based on established medical principles, which is a standard form of academic inquiry.\n- **Objectivity**: The problem is objective. It uses precise, defined terms and quantitative criteria. It is free of subjective language or opinion.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. It is scientifically sound, well-posed, objective, and contains all necessary information to arrive at a definitive solution and a conceptually reasoned explanation. The solution process may proceed.\n\n### Solution Derivation\n\nThe problem requires the calculation of the total CLASI damage score, which is defined as an additive index. The total score, which we will denote as $S_{\\text{damage}}$, is the sum of the scores from the two specified domains: discoid plaques and scarring alopecia.\n\nLet $S_{\\text{plaques}}$ be the score attributable to the discoid lupus plaques.\nLet $S_{\\text{alopecia}}$ be the score attributable to the scarring alopecia.\n\nThe total damage score is given by the sum:\n$$S_{\\text{damage}} = S_{\\text{plaques}} + S_{\\text{alopecia}}$$\n\n**Calculation of $S_{\\text{plaques}}$**:\nThe scoring for discoid plaques is based on the number of plaques, $N_p$, within a single anatomic region. The patient is stated to have $N_p = 8$ plaques, all localized to the cheeks, which constitutes one anatomic region. The scoring rule is:\n- $1$ point for $N_p \\leq 4$\n- $2$ points for $N_p \\geq 5$\n\nSince the patient has $8$ plaques, and $8 \\geq 5$, the score for this domain is:\n$$S_{\\text{plaques}} = 2$$\n\n**Calculation of $S_{\\text{alopecia}}$**:\nThe scoring for scarring alopecia is based on the longest diameter, $d$, of the largest scarred area. The patient has a single area with a longest diameter of $d = 5\\ \\mathrm{cm}$. The scoring rule is:\n- $1$ point for $d < 10\\ \\mathrm{cm}$\n- $2$ points for $d \\geq 10\\ \\mathrm{cm}$\n\nSince the patient's measurement is $5\\ \\mathrm{cm}$, and $5 < 10$, the score for this domain is:\n$$S_{\\text{alopecia}} = 1$$\n\n**Calculation of Total Damage Score**:\nThe total CLASI damage score is the sum of the individual component scores:\n$$S_{\\text{damage}} = S_{\\text{plaques}} + S_{\\text{alopecia}} = 2 + 1 = 3$$\n\nThe total CLASI damage score for this patient is $3$.\n\n### Conceptual Explanation of Damage Score in Guiding Therapy\n\nThe second part of the task requires an explanation of how the damage score guides therapeutic decisions, based on first principles.\n\nThe central first principle is the fundamental dichotomy between **disease activity** and **disease damage** in chronic inflammatory conditions like cutaneous lupus erythematosus.\n- **Disease Activity** refers to the active, ongoing inflammatory process. In cutaneous lupus, this manifests as erythema (redness), edema (swelling), and cellular infiltration. This process is dynamic and, critically, it is potentially **reversible** with appropriate anti-inflammatory or immunosuppressive therapy. The goal of therapy is to suppress activity.\n- **Disease Damage** refers to the permanent, **irreversible** changes that result from prior or inadequately controlled inflammation. This includes scarring (fibrosis), atrophy (thinning of the skin), and permanent follicular destruction leading to scarring alopecia. By definition, established damage cannot be reversed by current medical therapies.\n\nFrom these principles, the role of the damage score in guiding the intensity of therapy is not direct but rather prognostic and contextual.\n1.  **Damage Is Not the Therapeutic Target**: A high damage score, in isolation, does not justify an escalation of therapy. Applying potent immunosuppressive agents to an area of established scarring is scientifically unjustified, as the target of these drugs—active inflammation—is no longer present. Such a strategy would expose the patient to the risks of therapy without the possibility of benefit for the damaged tissue.\n\n2.  **Damage as a Prognostic Indicator**: The magnitude of the damage score is a quantitative record of the disease's cumulative impact. A high damage score indicates that the patient's disease has, historically, been aggressive or sub-optimally controlled, leading to significant tissue destruction. This identifies the patient as being at high risk for future damage accumulation if active inflammation is not rigorously controlled. Therefore, the damage score serves as a crucial prognostic marker.\n\n3.  **Contextualizing Current Activity**: The therapeutic decision is primarily driven by the **activity** score (which measures current, treatable inflammation). However, the damage score provides essential context. For example, a patient with a high damage score and even a moderate activity score presents a more urgent clinical scenario than a patient with no damage and the same moderate activity score. The high damage score demonstrates the destructive potential of the disease *in that specific patient*, emphasizing the critical need to extinguish all current activity to prevent the accrual of further irreversible harm.\n\n4.  **Informing Long-Term Strategy**: The damage score informs the long-term therapeutic goal. In a patient with extensive pre-existing damage, the primary goal is not to reverse this damage but to prevent any new damage from forming. This reinforces the importance of maintaining a state of minimal disease activity, using the safest, most effective long-term regimen. A rising damage score over time is objective evidence of treatment failure and is a powerful impetus to modify the therapeutic strategy.\n\nIn summary, the CLASI damage score does not directly dictate therapeutic intensity for the damage itself. Instead, it serves as an objective measure of past disease severity and a powerful prognostic tool. It quantifies the patient's risk profile and contextualizes the importance of controlling current disease activity, thereby guiding long-term management strategy with the explicit goal of preventing further irreversible tissue destruction.", "answer": "$$\n\\boxed{3}\n$$", "id": "4429851"}, {"introduction": "Effective management of cutaneous lupus involves not only choosing the right medication but also administering it safely. This final practice centers on hydroxychloroquine, a cornerstone therapy, and the critical need to prevent its most significant long-term side effect: retinal toxicity. This exercise will guide you through a practical, weight-based dose calculation and the reasoning behind modern ophthalmologic screening protocols, translating evidence-based guidelines into safe, individualized patient care. [@problem_id:4429919]", "problem": "A patient with cutaneous manifestations of systemic lupus erythematosus is initiated on hydroxychloroquine therapy. Current dosing recommendations for hydroxychloroquine in lupus emphasize limiting the daily dose to avoid retinal toxicity, using actual body weight rather than ideal body weight. Accepted risk factors for toxicity include exceeding the recommended daily dose per actual body weight, renal insufficiency, or concurrent tamoxifen use. Ophthalmologic screening guidance from the American Academy of Ophthalmology (AAO) recommends a baseline retinal examination within the first year of therapy and annual screening after a certain duration in patients without risk factors, with earlier or more frequent screening in patients who have risk factors. Historically, a cumulative dose threshold has been associated with increased risk.\n\nUsing these principles, answer the following for a 72 kg patient:\n1. Compute the maximum safe daily dose of hydroxychloroquine based on a limit of 5 mg/kg/day using actual body weight.\n2. Assuming the patient takes the maximum safe daily dose consistently, model the cumulative exposure as the time integral of the daily dose, $$D_{\\mathrm{cum}}(t)=\\int_{0}^{t} d\\,\\mathrm{d}\\tau,$$ where $d$ is constant. Using the historical cumulative dose threshold of 1000 g, compute the time in years required to reach this threshold. Use 365 days per year for the conversion from days to years. Express the final time in years rounded to three significant figures.\n3. In your derivation, justify the ophthalmologic screening intervals in relation to daily dose, duration of therapy, cumulative exposure, and the presence or absence of risk factors, starting from the AAO guidance stated above. Your numeric outputs should be: the maximum safe daily dose in $\\mathrm{mg}$/day and the time to reach a cumulative exposure of $1000$ g in years.\n\nFor the numeric answers:\n- Express the daily dose as an integer in $\\mathrm{mg}$/day.\n- Express the time in years rounded to three significant figures.", "solution": "The problem pivots on two well-established foundations: dose calculation per actual body weight for hydroxychloroquine to minimize retinal toxicity risk, and cumulative exposure as the time integral of a constant daily dose. The ophthalmologic screening recommendations stem from risk stratification based on dose relative to actual body weight, duration of therapy, and recognized risk factors.\n\n1. Maximum safe daily dose calculation:\nThe recommended ceiling dose is 5 mg/kg/day based on actual body weight. For a patient with mass $m=72$ kg, the maximum safe daily dose $d_{\\max}$ is\n$$\nd_{\\max} = 5 \\times m = 5 \\times 72 = 360 \\text{ mg/day}.\n$$\nThis uses the definition of weight-based dosing: daily dose equals recommended $\\mathrm{mg}/\\mathrm{kg}$/day multiplied by actual body weight in $\\mathrm{kg}$.\n\n2. Time to reach a cumulative dose threshold:\nCumulative dose is the integral over time of the instantaneous dose rate. Under constant dosing, $d$ is time-independent, so\n$$\nD_{\\mathrm{cum}}(t)=\\int_{0}^{t} d \\,\\mathrm{d}\\tau = d \\, t,\n$$\nwhere $t$ is in days if $d$ is expressed in $\\mathrm{mg}$/day or $\\mathrm{g}$/day. Convert the daily dose to grams: $d_{\\max}=360 \\text{ mg/day} = 0.360 \\text{ g/day}$. The time in days to reach $D_{\\mathrm{cum}}=1000 \\text{ g}$ is\n$$\nt_{\\mathrm{days}}=\\frac{D_{\\mathrm{cum}}}{d_{\\max}}=\\frac{1000}{0.360} \\text{ days} = 2777.\\overline{7} \\text{ days}.\n$$\nConvert days to years using 365 days per year:\n$$\nt_{\\mathrm{years}}=\\frac{t_{\\mathrm{days}}}{365}=\\frac{1000}{0.360 \\times 365}.\n$$\nCompute symbolically first, then numerically for the rounded output:\n$$\nt_{\\mathrm{years}}=\\frac{1000}{131.4} \\approx 7.612 \\ \\text{years}.\n$$\nPer the problem statement, round this to three significant figures:\n$$\nt_{\\mathrm{years}} \\approx 7.61.\n$$\n\n3. Ophthalmologic screening intervals justification:\nAmerican Academy of Ophthalmology (AAO) guidance indicates:\n- Baseline retinal examination within the first year of initiating hydroxychloroquine.\n- In patients without risk factors and dosed at or below 5 mg/kg/day actual body weight, the risk of toxicity remains low for the first several years, so annual screening begins after 5 years of therapy, with earlier re-screening not required in the absence of symptoms.\n- In the presence of recognized risk factors (daily dose exceeding 5 mg/kg/day, renal insufficiency reducing drug clearance, or concurrent tamoxifen use), annual screening is recommended from initiation after the baseline exam, potentially with heightened vigilance.\n- Historically, cumulative dose thresholds such as 1000 g have been associated with increased risk, but contemporary guidance emphasizes dose per actual body weight and duration of therapy as stronger predictors. In this patient at $d_{\\max}=0.360 \\text{ g/day}$, the 1000 g threshold would be reached at approximately $t_{\\text{years}} \\approx 7.61$ years, which is beyond the 5-year mark that triggers annual screening in low-risk patients. Therefore, for a 72 kg patient dosed at 360 mg/day without additional risk factors, a baseline exam within the first year followed by annual screening starting at year 5 is consistent with minimizing risk. If any risk factor exists, annual screening should commence immediately after baseline (that is, from year 0 of therapy), irrespective of cumulative dose.\n\nThus, the required numeric outputs are the maximum safe daily dose and the time to reach a cumulative exposure of 1000 g given the calculated dose and the conversion assumptions.", "answer": "$$\\boxed{\\begin{pmatrix}360 & 7.61\\end{pmatrix}}$$", "id": "4429919"}]}